Results 201 to 210 of about 89,235 (310)

Absence of Interaction Between 5α‐Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9543-9551, October 2026.
ABSTRACT Aims People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α‐reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co‐prescription of both drugs.
Haolan Tu, Chengsheng Ju, Stuart J. McGurnaghan, Luke A. K. Blackbourn, Scottish Diabetes Research Network Epidemiology Group, Peter Hanlon, Robert Lindsay, David McAllister, John Petrie, Naveed Sattar, Brian Kennon, Sam Philip, Scott Cunningham, Huan Wang, William Berthon, Helen Colhoun, Paul McKeigue, Sarah Wild, Ewan R. Pearson, Li Wei, Ruth Andrew   +20 more
wiley   +1 more source

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Journal of Internal Medicine, Volume 300, Issue 4, Page 461-479, October 2026.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Reduction in Prostacyclin Infusion Errors Following a Comprehensive Multidisciplinary Process Transformation for Hospitalized Pediatric Patients with Pulmonary Hypertension: A Quality Improvement Project. [PDF]

J Pediatr Pharmacol Ther
Kirk C, Davis A, Yung D.
europepmc   +1 more source

Peptide‐Enabled Nanoplatforms for Malaria and Leishmaniasis: From Intracellular Targeting to Translational Diagnostic Perspectives

ChemMedChem, Volume 21, Issue 18, 28 September 2026.
Peptide‐enabled nanoplatforms offer multifunctional strategies for the treatment and diagnosis of malaria and leishmaniasis. Liposomal, polymeric, and metallic nanocarriers, together with cell‐penetrating peptides and parasite‐derived mimotopes, can improve targeted drug delivery, stability, bioavailability, and intracellular localization.
Christian S. Carnero Canales, Ana Clara Lunardi Yagi, Túlio Custódio Reis, Jessica Ingrid Cazorla, Jade Rojas Villar, Marcia A. Graminha, Roxana Yesenia Pastrana Alta, Fernando Rogério Pavan   +7 more
wiley   +1 more source

Solving the degradation problem of continuous ceftazidime infusions-the Cooltaz study. [PDF]

Antimicrob Agents Chemother
La Vita SL, Liu B, Bryant PA.
europepmc   +1 more source

Bio‐Inspired Biopolymeric Implantable Platform for Localized and Sustained Drug Delivery in Solid Tumor Treatment

Advanced Functional Materials, Volume 36, Issue 73, 10 September 2026.
A bio‐inspired biopolymeric implantable drug delivery platform enables localized and sustained release of 7‐ethyl‐10‐hydroxycamptothecin (SN‐38) in solid tumor treatment. The three‐dimensional (3D) structured crosslinked‐chitosan implants are fabricated via 3D‐printed molds and provide drug release over 3 months, significantly inhibiting tumor growth ...
Mercedes Lozano‐Garcia, Constantine Vogiatzis, Alejandra Planells‐Devesa, Emre Dikici, Caroline Vieira Maluf, Vasudev Vivekanand Nayak, Paulo G. Coelho, Lukasz Witek, Alicia Bilbao, Daniel Bilbao, Prasoon Mohan, Sapna Deo, Sylvia Daunert   +12 more
wiley   +1 more source

A Simple Mixing and Infusion Set for Parenteral Nutrition

Transfusion Medicine and Hemotherapy, 1976
openaire   +2 more sources

Nanomaterial Strategies for Pulmonary Delivery of Immunotherapeutics in Lung Cancer Treatment

Advanced Healthcare Materials, Volume 15, Issue 34, 11 September 2026.
Inhalable immunotherapeutic nanomedicines enable organ‐selective immune modulation by overcoming pulmonary delivery barriers and concentrating therapy within lung tumors. This Review defines how nanomaterial properties govern airway deposition, retention, cellular partitioning, and immune activation across vaccines, checkpoint blockade, STING agonists,
Han Zhang, Wei Tang
wiley   +1 more source

Hydromorphone in Pediatric Pain Management: Pharmacology, Clinical Applications, and Safety Considerations-A Narrative Review. [PDF]

Healthcare (Basel)
Vittori A, Di Fabio C, Mascilini I, Francia E, Pescatore S, Cecchetti C, Marchetti G, Marinangeli F, Grimaldi Capitello T, Cascella M.   +9 more
europepmc   +1 more source

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children

American Journal of Hematology, Volume 101, Issue 9, Page 2297-2310, September 2026.
ABSTRACT Hydroxyurea (HU) is the most widely prescribed disease‐modifying treatment in sickle cell disease (SCD), though treatment responses vary due to metabolism and adherence. We examined HU blood levels and treatment response in patients with homozygous sickle cell disease (HbSS).
Sigrid van der Veen, Bart J. Biemond, Marjon H. Cnossen, Pablo Bartolucci, Maria P. Boaro, Betzabel Cajiao Garcia, Raffaella Colombatti, M. D'Agnolo, Karin Fijnvandraat, Anna Collado Gimbert, Amira Idrizovic, Petros Kountouris, Mar Mañú‐Pereira, Elisabetta Mezzalira, Mariane de Montalembert, Erfan Nur, A. Pham Hung D' Alexandry D'Orengiani, Tiziana Sanavia, Saskia E. M. Schols, Marissa J. M. Traets, Minke A. E. Rab, Sara I. Reidel, Anita W. Rijneveld, Yosr Zaouali, Nanda M. Verhoeven‐Duif, Judith J. M. Jans, Eduard J. van Beers   +26 more
wiley   +1 more source